CompletedNot applicableNCT02958930

Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NeuroEM Therapeutics, Inc.
Principal Investigator
Amanda Smith, MD
Byrd Alzheimer's Institute, University of South Florida
Intervention
MemorEM 1000(device)
Enrollment
8 enrolled
Eligibility
63 years · All sexes
Timeline
20172019

Study locations (1)

Collaborators

Byrd Alzheimer's Institute, University of South Florida · University Diagnostic Institute, Tampa · Invicro, Boston · Left Coast Engineering, Escondido

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02958930 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials